Press Releases Instil Bio, Inc.

Equities

TIL

US45783C2008

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
10.69 ^USD	-3.17%		-3.13%	+40.29%

May. 13	Baird Adjusts Price Target on Instil Bio to $32 From $54, Maintains Outperform Rating	MT
May. 10	Instil Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update	May. 10	AQ
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	Mar. 21	AQ
Instil Bio Announces Strategic Update	Jan. 16	AQ
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split	Dec. 05	AQ
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update	Nov. 13	AQ
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting	Nov. 06	AQ
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update	23-08-14	AQ
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference	23-06-26	AQ
INSTIL BIO, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	23-05-11	AQ
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update	23-05-11	AQ
INSTIL BIO, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-31	AQ
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update	23-03-31	GL
INSTIL BIO, INC. : Other Events (form 8-K)	23-03-10	AQ
INSTIL BIO, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	23-02-27	AQ
INSTIL BIO, INC. : Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits (form 8-K)	23-02-01	AQ
Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site	23-01-31	AQ
INSTIL BIO, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	23-01-27	AQ
INSTIL BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	23-01-09	AQ
Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer	23-01-09	AQ
Newman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL)	22-12-12	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Instil Bio, Inc.

Equities

TIL

US45783C2008

Press Releases

Filters